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A B S T R A C T
Purpose
A key challenge in the treatment of advanced non–small-cell lung cancer (NSCLC) is improving
outcomes for patients who have achieved at least stable disease after standard first-line therapy.
Although current guidelines recommend a maximum of six cycles of first-line therapy, even in
responding patients, recent trials have shown benefit with maintenance therapy.
Methods
We reviewed the English literature for randomized controlled trials on prolonged therapy for
NSCLC conducted between January 1999 and January 2010. The search was supplemented by a
review of abstracts presented at the American Society of Clinical Oncology annual meetings (2004
to 2010), the World Lung Cancer Conference (2007 to 2009), and the 2009 Joint European CanCer
Organisation-European Society for Medical Oncology conference.
Results
Several alternative strategies for prolongation of chemotherapy have been tested: these can be
broadly categorized as continuation (prolongation of the first-line regimen until disease progres-
sion, unacceptable toxicity, or administration of a predefined greater number of treatment cycles),
switch-maintenance (administration of an active agent immediately after completion of the initial
course of chemotherapy), and continuation-maintenance (ongoing administration of a lower
intensity version of the first-line chemotherapy regimen). These approaches differ from traditional
second line, which is defined as treatment administered after documented clinical progression
subsequent to first-line therapy.
Conclusion
There are no data to support continuation chemotherapy in advanced NSCLC. Switch-maintenance
trials with erlotinib and pemetrexed have demonstrated an improvement in overall survival. Thus
far, continuation-maintenance has shown an improvement in progression-free survival, without an
overall survival advantage.
J Clin Oncol 28:5116-5123. © 2010 by American Society of Clinical Oncology
INTRODUCTION
An estimated 215,000 new instances of lung cancer
were diagnosed in the United States in 2008,1 with
most of these cases ( 80%) categorized as non–
small-cell lung cancer (NSCLC). The majority of
patients with NSCLC present with locally advanced
( 35%) or metastatic disease ( 40%),1 and in this
palliative setting balancing efficacy with toxicity is of
the utmost importance.
Platinum-based doublets are the mainstay of
standard chemotherapy for patients with good per-
formance status who have advanced NSCLC.2,3
Adding targeted agents, such as bevacizumab4 or
cetuximab,5 to standard chemotherapy can, in se-
lected groups of patients, increase the overall sur-
vival (OS).
The purpose of this article is to review recent
studies that have evaluated strategies aimed at pro-
longing the duration of chemotherapy in eligible
patients with NSCLC, and to discuss the advantages/
disadvantages and current clinical objectives of the
different approaches.
METHODS
Information for this review was derived from a search of
the PubMed database using the following search strategy:
(NSCLC AND [advanced OR metastatic]) AND (sequen-
tial OR prolonged OR strategy OR second-line OR sched-
ule OR maintenance). The search was restricted to
randomized controlled trials (RCT) published in English
between January 1999 and January 2010. Primary citations
were hand searched and relevant secondary publications
identified. The search was supplemented by a review of
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abstracts presented at the American Society of Clinical Oncology (ASCO)
annual meeting (2004 to 2010), the World Lung Cancer Conference (2007 to
2009), and the 2009 Joint European CanCer Organisation-European Society
for Medical Oncology conference.
Strategies to Optimize Therapy
The optimal duration of chemotherapy in advanced NSCLC was the
subject of a recent meta-analysis.6 The analysis covered 13 RCTs and found
that continuing chemotherapy beyond 3 or 4 cycles significantly increased
progression-free survival (PFS) with a hazard ratio (HR) of 0.75 (95% CI, 0.69
to 0.81; P  .0001). Improvement in OS was associated with a statistically
significant, but marginal, HR of 0.92 (95% CI, 0.86 to 0.99; P .03). Adverse
events were also more common with longer-duration therapy, although qual-
ity of life (QoL) data were not available for six of the studies. Although this
study evaluated a wide variety of prolonged treatment strategies, the authors
found no significant differences based on the specific strategy chosen. The
same conclusion was reached in a meta-analysis performed by Lima et al.7 This
study targeted seven RCTs of a defined number of chemotherapy cycles versus
continuing treatment until disease progression or a higher number of cycles.
Treatment with more than 4 cycles was associated with an improved PFS (HR,
0.75; P .001) in the absence of an OS benefit (HR, 0.97; P .65). Current
guidelines from the National Comprehensive Cancer Network, ASCO, and the
European Society of Medical Oncologists all recommend up to a maximum of
6 and a minimum of 4 cycles of first-line platinum-based doublet chemother-
apy for responding patients or those with stable disease.2,3
A key challenge is to improve the outcome of eligible patients who have
received adequate first-line therapy and have achieved at least stable disease.
Before discussing the options, it is worth considering what proportion of
patients actually receives second-line therapy. Evidence from recent major
clinical trials, such as the Eastern Cooperative Oncology Group (ECOG) 4599
study,4 the trial comparing cisplatin/pemetrexed with cisplatin/gemcitabine,8
and First-Line Erbitux in Lung Cancer (FLEX)5 suggest this figure is approxi-
mately 50% to 60% of patients receiving first-line therapy.
Although several approaches have been investigated for the prolongation
of therapy duration in patients with advanced NSCLC, there are currently no
formal or well-accepted definitions for the various strategies used. Most inves-
tigators accept the term continuation therapy as the prolongation of the
first-line chemotherapy. For the purpose of this review, we have used the
definitions given by National Comprehensive Cancer Network for mainte-
nance treatment (continuation-maintenance and switch-maintenance).
Continuation Therapy
Continuation in the context of strategies for prolonging therapy in ad-
vanced NSCLC involves continuing the first-line regimen until disease pro-
gression, unacceptable toxicity, or administration of a predefined greater
number of treatment cycles.
A number of studies reported that continuation of initial chemotherapy
beyond 4 to 6 cycles is not associated with improved response rate or survival,
even in patients with stable or responsive disease. The first study was the
randomized trial conducted by Smith et al.9 In this trial, patients were ran-
domly assigned to either 3 or 6 cycles of mitomycin, vinblastine, and cisplatin.
There were no differences between the two regimens in terms of median
survival (6 v 7 months), 1-year survival (22% v 25%), or duration of symptom
relief (4.5 months in both groups), while some QoL measures were better in
the 3-cycle arm. While more than 70% of the patients completed 3 cycles of
therapy, fewer than one third were able to receive 6 cycles. The study con-
ducted by Socinski et al10 compared a regimen of carboplatin and paclitaxel
given every 3 weeks for either 4 cycles (arm A) or continuously until progres-
sion (arm B). Patients received second-line treatment (after the scheduled 4
cycles in arm A or at progression in arm B) comprising weekly paclitaxel 80
mg/m2. There were no significant differences between the two arms in terms of
OS (6.6 v 8.5 months; P  .63) or QoL, as measured using the Functional
Assessment of Cancer Therapy-Lung instrument. Moreover, clinically rele-
vant neuropathy was much more common in patients receiving prolonged
paclitaxel (27% v 14%). The lack of a significant difference in survival between
the study arms was evident both in the overall population and when compar-
ing subgroups of patients who had received at least 4 treatment cycles.
In the other study, von Plessen et al evaluated carboplatin (area under the
curve, 4 by Chatelut, day 1) plus vinorelbine (25 mg/m2, days 1 and 8) every 3
weeks given for either 3 or 6 cycles.11 There was no significant difference in OS
(28 weeks [3 cycles] v32 weeks [6 cycles];P .75) or PFS (16 weeks [3 cycles] v
21 weeks [6 cycles]; P  .21). In addition, QoL assessment up to 26 weeks
(using the European Organisation for the Research and Treatment of Cancer
Quality of Life Questionnaire 30 or Quality of Life Questionnaire LC13 [Lung
Cancer module]) was not significantly different between the two groups, in
terms of global QoL, pain, and fatigue.
Although the results of these studies were indicative of a lack of benefit
with continuation chemotherapy in patients with advanced NSCLC, it is
important to note that the majority of patients randomly assigned to longer
courses of chemotherapy did not receive the planned number of cycles because
of toxicity or disease progression. In the study by Socinski, only 57% of patients
in arm A completed the scheduled 4 cycles of therapy, while in the continuous
treatment arm, the median number of cycles administered was 4 (range, 0 to
19), with 42% and 18% of patients receiving more than 4 and  8 cycles,
respectively. In the study by von Plessen, 78% to 79% of patients across the
study completed 3 cycles of therapy; however, only 54% of patients assigned to
the longer regimen completed 6 cycles of therapy.
Continuation-Maintenance Therapy
Ongoing administration of a lower intensity version of the first-line
regimen can be termed continuation-maintenance therapy. Because it uses a
less intensive regimen, maintenance therapy could facilitate more consistent
delivery of chemotherapy compared with continuation therapy.
In a study conducted by Belani et al12, patients were initially randomly
assigned to one of three paclitaxel/carboplatin regimens(Tables 1 and 2).12-15
Patients who responded after 4 cycles were randomly assigned to either weekly
low-dose paclitaxel or to observation only. Although the study was not pow-
ered to compare outcomes during the maintenance phase, both time to pro-
gression (38 v 29 weeks) and OS (75 v 60 weeks) were longer in patients who
received maintenance paclitaxel. Another trial evaluated maintenance gemcit-
abine versus best supportive care (BSC) after induction treatment with 4 cycles
of gemcitabine and cisplatin.13 Patients with responsive or stable disease were
randomly assigned to maintenance gemcitabine or to BSC only. Time to
progression, which was the primary end point, was significantly longer for
patients who received maintenance therapy, both throughout the entire study
period (6.6 v 5 months;P .001) and during the randomization period (3.6 v
2 months). There was also a trend toward longer OS throughout the entire
study in the maintenance gemcitabine group. The study noted no significant
differences in QoL between the two arms.
Two additional studies with maintenance gemcitabine were recently
reported.14,15 In the first study, patients with stable or responsive disease were
randomly assigned to either gemcitabine with BSC or BSC alone. The study
closed after 6 years due to slow accrual, at which point 179 of the 238 planned
events had occurred. Moreover, a large portion of the patients in both cohorts
had a performance status (PS) of 2 to 3. Not surprisingly, the rate of second-
line therapy for the control group was very low, at 17%. There was no differ-
ence in PFS, calculated from first-line therapy (maintenance, 7.4 months; BSC,
7.7 months), or OS (maintenance, 8 months; BSC 9.3 months). It appears that
poor PS patients may not be good candidates for ongoing chemotherapy. The
second study, however, showed a strong PFS benefit for those patients, who
continued gemcitabine after four cycles of cisplatin and gemcitabine induc-
tion. The design of this French study (Intergroupe Francophone de Cancer-
ologie Thoracique-Groupe Francais de Pneumo-Cancerologie [IFCT-GFPC]
0502) randomly assigned patients to observation or two different maintenance
regimens, gemcitabine, or erlotinib. Moreover, it mandated second-line ther-
apy for all patients with pemetrexed. Since the study was designed before the
interaction of pemetrexed with histology was known, 19% of patients in the
observation group had squamous cell histology. Independently assessed PFS
was longer in the gemcitabine arm (3.8 v 1.9 months; HR, 0.55; P .001). OS
was a secondary end point and with 69.6% of events having occurred, the HR
of the comparison between gemcitabine and observation is 0.86 (95% CI, 0.66
to 1.12). Impressively, 81.9% of patients in the observation arm received US
Food and Drug Administration–approved second-line therapy, which is the
highest salvage therapy rate reported in maintenance trials and balances much
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better the two arms in terms of overall therapy delivered. Unfortunately, with
about 150 patients randomly assigned in each arm, this trial may not have the
power to detect any clinically meaningful survival differences.
Despite complete lack of randomized data, maintenance therapy with
bevacizumab or cetuximab is currently recommended after induction with
antibody containing chemotherapy, based on the design of ECOG 4599
and FLEX.2
Switch-Maintenance Therapy
Switch-maintenance therapy involves the administration of an agent
with established activity in advanced NSCLC, immediately after completion of
the initial course of chemotherapy. Although any active agent against NSCLC
could be considered for maintenance therapy, switch-maintenance trials thus
far have only evaluated approved second-line agents (docetaxel,16,17 erlo-
tinib,18 and pemetrexed19).
Preclinical and clinical data have shown that taxanes, such as docetaxel,
are active in platinum-resistant NSCLC,20,21 indicating that the delivery of
taxanes after platinum-based induction therapy using a switch-maintenance
strategy may be a viable option. A phase III study involving 566 patients with
stage IIIB/IV NSCLC evaluated this approach directly (Tables 3 and 4).15,22-26
The study evaluated the relative efficacy of docetaxel given either immediately
after first-line therapy or at disease progression. This is the only study to date
that has examined directly the issue of chemotherapy timing, since both
groups were scheduled to receive the same regimen. Of the original cohort, 309
patients completed first-line treatment consisting of 4 cycles of carboplatin
and gemcitabine and were randomly assigned to immediate or delayed do-
cetaxel for a maximum of 6 cycles. Median PFS was significantly longer in the
immediate versus the delayed docetaxel group (5.7 v 2.7 months; P .0001).
There was also a nonsignificant trend toward longer OS in the immediate
docetaxel group (12.3 v 9.7 months;P .0853). A significant proportion of
patients in the delayed treatment arm never received docetaxel (although
63% were able to receive therapy), compared to the immediate arm, where
almost all patients did. The major reason for not receiving chemotherapy
in the delayed arm was significant symptomatic deterioration by the time
disease progression occurred. Analysis of patients who actually received
docetaxel revealed that OS was identical in both arms of the study (12.5
months), possibly indicating that the trend toward improved OS was
because more patients in the immediate group were able to receive do-
cetaxel treatment. Toxicity profiles were generally similar between the
arms. Comparisons of QoL, measured during chemotherapy for patients
in the immediate arm and during observation in the delayed arm, showed
no significant differences.
The potential utility of early second-line therapy with the antifolate
pemetrexed was investigated in a phase III trial.23 A total of 663 patients
who had not progressed after 4 cycles of platinum-based induction therapy
Table 1. Patient Characteristics in Trials of Continuation-Maintenance Therapy
Characteristic
Study and Agent
Belani (2003)12
Paclitaxel
Brodowicz (2006)13
Gemcitabine
Belani et al (2010)14
Gemcitabine
Pérol et al (2010)15
Gemcitabine
Maintenance Yes No Yes No Yes No Yes No
No. of patients 65 65 138 68 128 127 154 155
Age, years 66 65 58 56 67.2 67.5 57.9 59.8
Male, % 63 62 70.2 79.4 60 67 73 73
Performance status 0-1, % 91 92 47.8 48.5 44 43 94 97
Stage IV, % 72 78 72.5 73.5 78 91 91 91
Adenocarcinoma, % NR NR 44.9 39.7 NR NR 66 67
Squamous, % NR NR 42 38.2 NR NR 22 19
Never smokers, % NR NR NR NR NR NR 38 38
Abbreviation: NR, not recorded.
Percentage of patients with Karnofsky performance status  80.
Table 2. Summary of Trials Investigating Continuation-Maintenance Therapy
Study Year Induction Therapy Maintenance Therapy
Median
TTP/PFS Median OS Main Grade 3/4 Toxicities
Belani et al12 2003 Paclitaxel/carboplatin (random
assignment to one of
three regimens)
Paclitaxel 70 mg/m2 weekly
for 3 of 4 weeks
38 weeks 75 weeks All grade 3/4 toxicities: 45% for
paclitaxel maintenance
Observation 29 weeks 60 weeks
Brodowicz
et al13
2006 Gemcitabine 1,250 mg/m2 on
days 1 and 8 plus cisplatin
80 mg/m2 on day 1 every
3 weeks for up to 4 cycles
Gemcitabine 1,250 mg/m2
days 1 and 8 plus BSC
6.6 months 13.0 months Maintenance gemcitabine: ANC, 14.9%;
PLT, 1.7%; blood transfusion: 20.0%
(gemcitabine), 6.3% (BSC)BSC 5.0 months;
P  .001
11.0 months
Belani et al14 2010 Carboplatin AUC 5 on day 1;
gemcitabine 1,000 mg/m2
on days 1, 8  4 cycles
Gemcitabine 1,000 mg/m2
on days 1 and 8 plus
BSC
7.4 months;
P  .575
8.0 months;
P  .838
ANC: 15% chemo, 2% BSC PLT: 9%
chemo, 4% BSC fatigue: 5% chemo-
therapy, 2% BSC
BSC 7.7 months 9.3 months
Pérol et al15 2010 Cisplatin 80 mg/m2 on day 1;
gemcitabine 1,250 mg/m2
on days 1, 8  4 cycles
Gemcitabine 1,250 mg/m2
days 1 and 8 plus BSC
3.8 months;
P  .001
NR At least 1 grade 3/4 AE: chemotherapy
27.9%, observation 2.6%
Observation 1.9 months NR
Abbreviations: TTP, time to progression; PFS, progression-free survival; OS, overall survival; BSC, best supportive care; ANC, absolute neutrophil count; PLT,
platelets; AE, adverse event.
TTP and OS were adjusted for 16 weeks of initial treatment for the study by Belani et al (2003).12 PFS was calculated from first-line therapy in the study by Belani
et al (2010).14 In the other studies, TTP and PFS were calculated from time of random assignment.
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were randomly assigned in a 2:1 ratio to receive pemetrexed plus BSC or
placebo plus BSC. Pemetrexed was not used in the induction regimens.
Patient characteristics were well-balanced between the two groups. Main-
tenance therapy significantly improved the independently assessed PFS
(4.0 v 2.0 months; HR, 0.60; P  .001) and OS (13.4 v 10.6 months; HR,
0.79; P .012) compared with placebo. The clinical benefit of pemetrexed
was only evident in patients with nonsquamous histology (PFS, 4.4 v 1.8
months; HR, 0.47; P .001; OS, 15.5 v 10.3 months; HR, 0.70; P .002),
while a predefined analysis in patients with squamous cell histology
showed no improvement in any survival end point (PFS: 2.4 v 2.5 months;
HR, 1.03; OS: 9.9 v 10.8 months, HR, 1.07). A large portion of patients
assigned to placebo received second-line therapy (67%), although only
18% actually received pemetrexed. Other active agents included docetaxel
(29%), erlotinib (21%), and gefitinib (10%).
Table 3. Patient Characteristics in Trials of Switch-Maintenance Chemotherapy
Characteristic
Study and Agent
Fidias et al
(2008)22
Docetaxel
Ciuleanu et al
(2009)23
Pemetrexed
Cappuzzo et al
(2009)24
Erlotinib
Miller et al
(2009)25
Erlotinib
Pérol et al
(2010)15
Erlotinib
Maintenance Yes No Yes No Yes No Yes No Yes No
No. of patients 153 156 441 222 438 451 370 373 155 155
Age, years 65.4 65.5 60.6 60.4 60 60 64 64 56.4 59.8
Male, % 62.1 62.2 73 73 73 75 52.2 52.3 73 73
Performance status 0-1, % 94.1 89.7 100 100 100 100 100 100 94 97
Stage IV, % 82.4 83.3 82 79 74 76 85.6 83.3 93 91
Adenocarcinoma, % 54.9 46.8 50 48 47 44 81.3 82.5 63 67
Squamous, % 16.3 18.6 26 30 38 43 3 1.6 17 19
Never smokers, % NR NR 26 28 18 17 16.5 17.7 38 38
Abbreviation: NR, not recorded.
Peripheral squamous cell cancers.
Table 4. Summary of Randomized Controlled Trials Investigating Switch-Maintenance Therapy
Study Year Induction Intervention
Median PFS
(months)
Median OS
(months) Main Grade 3/4 Toxicities QoL
Fidias et al22 2008 CG  4 cycles Immediate docetaxel
75 mg/m2 every 3
weeks (maximum of
6 cycles)
5.7 12.3 Neutropenia, 27.6%;
febrile neutropenia, 3.5%;
fatigue, 9.7%
No significant
difference
Delayed docetaxel 75
mg/m2 every 3
weeks at first
evidence of PD
2.7;
P  .001
9.7;
P  .0853
Neutropenia, 28.6%;
febrile neutropenia, 2%;
fatigue, 4.1%
Ciuleanu et al23 2009 Platinum-based
doublet  4
cycles
Pemetrexed 500 mg/
m2 every 3 weeks 
BSC
4.0 13.4 Total, 16%;
fatigue, 5%;
anemia, 3%;
infection, 2%
Favored pemetrexed
for control of pain
and hemoptysis
BSC 2.0;
P  .001
10.6;
P  .012
Total, 4%;
fatigue,  1%;
anemia,  1%;
infection, 0%
Capuzzo et al24 2009 Platinum-based
doublet  4
cycles
Erlotinib 150 mg/d 12.3 weeks 12.0 Rash, 9%;
diarrhea, 2%;
rash, 0%;
diarrhea, 0%
No difference in
global QoL;
time to pain
favored erlotinib
Placebo 11.1 weeks;
P  .001
11.0;
P  .0088
Miller et al25 and
Kabbinavar
et al26
2009 Platinum-based
doublet and
bevacizumab 
4 cycles
Bevacizumab 15 mg/kg
every 3 weeks 
erlotinib 150 mg/d
4.76 15.9 Total, 44.1%;
rash, 10.4%;
diarrhea, 9.3%
NR
2010 Bevacizumab 15 mg/kg
every 3 weeks 
placebo
3.75;
P  .0012
13.9;
P  .2686
Total, 30.4%;
rash, 0.5%;
diarrhea, 0.8%
Pérol et al15 2010 CisG  4 cycles Erlotinib 150 mg/d 2.9 months NR Total, 15.5%;
rash, 9%;
diarrhea, 0.6%
NR
Observation 1.9 months;
P  .002
Total, 2.6%;
rash, 0%;
diarrhea, 0%
Abbreviations: PFS, progression-free survival; OS, overall survival; QoL, quality of life; CG, carboplatin area under the curve 5 day 1, gemcitabine 1,000 mg/m2 days
1 and 8; PD, progressive disease; BSC, best supportive care; NR, not reported; CisG, cisplatin 80 mg/m2 day 1, gemcitabine 1,250 mg/m2 days 1 and 8.
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Based on its efficacy in advanced NSCLC, the epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib has also been eval-
uated as switch-maintenance therapy in three randomized phase III studies
(Sequential Tarceva in Unresectable Lung Cancer [SATURN], ATLAS,
and IFCT-GFCP 0502). Results from the SATURN study were recently
published.24 This trial evaluated erlotinib maintenance therapy at 150 mg/d
versus placebo in 889 patients without disease progression after treatment with
at least 4 cycles of standard first-line platinum-based doublet chemotherapy.
Rash (erlotinib 60% v placebo 8%) and diarrhea (20% v 3%) were the most
common toxicities, with most reported to be of grade 1/2. Patients in the
erlotinib arm had significantly prolonged PFS compared with placebo, in both
the unstratified (12.3 v 11.1 week; HR, 0.71;P .001) and EGFR immunohis-
tochemistry (IHC) –positive study populations (12.3 v 11.1 week; HR, 0.69;
P .001). More importantly, survival was increased in the erlotinib arm, both
in the intent to treat population (12.0 v 11.0 months; HR, 0.81;P .0088) and
in the subgroup of patients with wild-type EGFR (11.3 v 10.2 months; HR,
0.77; P  .0243). Although 72% of patients in the placebo arm received
second-line therapy, only 21% actually received an EGFR-TKI. Interestingly,
subgroup analysis according toEGFRmutation status showed that the major-
ity of the benefit was driven by the patients with wild-type, rather than mutant,
EGFR tumors (HR, 0.77 v 0.83).27 Biomarker analysis of the SATURN trial
evaluated the role of EGFR copy number by fluorescent in situ hybridization
(FISH; positive in 48%), EGFR expression by IHC (positive in 84%), K-ras
mutation (positive in 18%), and EGFR mutation (positive in 11% of samples
tested).28 In this analysis, there was a significant interaction between the
presence of EGFR mutation and treatment benefit with erlotinib, in terms of
PFS (P .001).
The ATLAS study compared bevacizumab plus erlotinib with bevaci-
zumab plus placebo in 743 patients with advanced NSCLC without progres-
sion after 4 cycles of platinum doublet chemotherapy plus bevacizumab.25
ATLAS is therefore unique among these trials, since its design incorporates
standard bevacizumab maintenance in both arms. PFS was significantly longer
in the combination maintenance group (4.76 v 3.75 months; HR, 0.722;
P  .0012). The 3- and 6-month PFS rates was 67.7% and 40.3% in the
erlotinib arm, compared to 53.4% and 28.4% for the placebo arm. Not sur-
prisingly, subgroup analysis showed a significant effect on PFS for never
smokers treated with maintenance erlotinib (HR, 0.34). Biomarker status
was available in 367 of the patients in the trial, and similar to SATURN,
evaluated the influence of EGFR IHC (positive in 52% of available speci-
mens), EGFR FISH (positive in 23.7%), EGFR mutation (positive in 14%),
and K-ras mutation (positive in 25%) on PFS.29 Patients who were EGFR
FISH positive, EGFR mutated, and K-ras wild-type enjoyed the greatest
benefit from therapy with erlotinib and bevacizumab in the maintenance
setting (HR, 0.66, 0.44, and 0.67, respectively). OS, which was a secondary
end point, showed a nonsignificant 2-month difference in favor of the
experimental group (15.9 v 13.9 months; HR, 0.9; P  .2686). The high
baseline OS in the bevacizumab arm, the highest reported in maintenance
trials, could be due to patient selection, or effect of bevacizumab in the
maintenance setting. Potentially, the addition of another maintenance
agent does not confer any additional benefit. Alternatively, based on the
number of patients randomly assigned and the high survival attained by
the bevacizumab only group, the study may not have had the power to
detect OS differences. It has to be noted that the study closed after a second
interim analysis confirmed the PFS superiority in the erlotinib arm, which
limits the interpretation of this posthoc analysis.
The recently reported IFCT-GFPC 0502 compared erlotinib to observa-
tion after 4 cycles of cisplatin/gemcitabine.15 As mentioned previously, pa-
tients were mandated to receive pemetrexed on progression, and indeed a large
portion of these patients was treated (pemetrexed, 76.1%; erlotinib, 3.9%; and
docetaxel, 1.9%). Baseline characteristics were balanced. Similar to the previ-
ous studies, PFS favored the erlotinib group (2.9 v 1.9 months; HR, 0.82;
P .002). OS comparison showed an HR of 0.91 (95% CI, 0.80 to 1.04) in a
preliminary evaluation. Although tissue was submitted for EGFR mutation
analysis, results based on mutation status are not currently available. It is
interesting, however, that there was no difference in the PFS HR between
smokers and nonsmokers in this study (HR 0.79 for smokers and HR 0.88
for nonsmokers).
DISCUSSION
Optimizing the treatment of advanced NSCLC involves consideration
of delivering the most effective therapies, in the right combination, at
the right time, while minimizing toxic adverse effects and adverse
effects on QoL. Approximately 40% to 60% of patients with advanced
NSCLC complete 4 cycles of platinum-based chemotherapy without
progression or unacceptable toxicity. For these patients, continuation
of chemotherapy is a feasible option. The question of how to deliver
this additional therapy is the subject of ongoing clinical research.
The US Food and Drug Administration and the European Com-
mission approved pemetrexed in July 2009 as maintenance therapy for
patients with nonsquamous histology, for whom disease has not pro-
gressed after platinum-based chemotherapy.30,31 Of interest, the Eu-
ropean Medicines Agency (EMEA) specifically noted that first-line
treatment should be a platinum doublet with gemcitabine, paclitaxel,
or docetaxel.30 Erlotinib as immediate treatment after first-line chem-
otherapy was also recently approved by the US Food and Drug Ad-
ministration32 and the EMEA.33 It has to be noted that although the
docetaxel study22 was negative, the HR for PFS and OS was fairly
consistent with the other switch-maintenance trials (Table 5), suggest-
ing that the lack of statistical significance may relate more to the power
of the study than a lack of effectiveness of the strategy.
It is unclear whether the benefit seen in recent maintenance
studies is the result of the early institution of noncrossresistant
therapy or more practical considerations. Despite strong theoreti-
cal rationale,34 the planned sequential delivery of noncrossresistant
agents has not proven beneficial in advanced NSCLC.35,36 A main-
tenance approach may therefore represent the most effective way
to deliver second-line therapy. This is an important point to con-
sider since typically only approximately 60% of patients are able to
receive second-line treatment. The IFCT-GFPC-0502 study is very
critical in that respect, with more than 80% of patients in the control
group actually receiving US Food and Drug Administration–
approved treatment. Unfortunately, the trial has limited power to
detect survival differences.
A number of additional issues relevant to the delivery of chemo-
therapy in NSCLC are worth discussing. Who will receive second-line
therapy? Results from the docetaxel study show that patients who
actually receive chemotherapy in either arm have identical survival at
12.5 months. Although this is a biased analysis, it may suggest that
timing is less important than the ability to receive therapy at time of
progression. However, is it possible to predict who will receive second-
line therapy? Currently, data are only available for the docetaxel study,
where factors such as complete response/stable disease (SD), sex, PS,
stage IIIB versus IV were examined; however, no characteristic was
found that would predict for eventual second-line therapy in the
control group.
How should we select patients, who will benefit from mainte-
nance therapy? Results from the docetaxel study suggested that re-
sponse patients might benefit more than patients with SD. The HR for
PFS was 0.47 and 0.81, while for OS the HR was 0.61 and 1.02 for
response and SD patients, respectively. Similarly, the PFS HR in the
French study with continuation gemcitabine maintenance favored the
Fidias and Novello
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responsive patients (HR, 0.44 v 0.68), while there was no difference in
the switch-maintenance approach with erlotinib between response
and SD patients (HR, 0.80 v 0.85, respectively). Subgroup analysis of
the pemetrexed study showed improvement only for patients with SD
at time of random assignment.37 The HR for PFS was 0.53 for re-
sponders and 0.48 for SD patients, whereas the HR for OS was 0.90
and 0.68, respectively. Data from SATURN were concordant with the
pemetrexed trial; patients with responsive tumors had an OS HR of
0.94 versus 0.72 for SD.24 It is important to note that EMEA approved
erlotinib only for patients with SD after 4 cycles of standard platinum-
based first-line chemotherapy, although as it can be seen from the
above the data is not consistent at all.
Another interesting point comes from the SATURN study, where
the benefit in PFS was primarily seen in patients withEGFRmutations,
whereas the benefit in OS was driven byEGFRwild-type patients. This
suggests that in patients with EGFR mutant tumors, for whom highly
effective salvage therapy exists, timing is less important. Unfortu-
nately, such a beneficial effect is not seen with usual chemotherapy.
Results from the pemetrexed study clearly showed benefit only
for patients with nonsquamous histology, presumably due to the
higher level of thymidylate-synthase in squamous cell cancers.38 Al-
though the HR in the SATURN study also favored patients with
adenocarcinoma histology, both in terms of PFS (HR 0.60 v 0.76 for
squamous cell cancers) and OS (HR 0.77 v 0.86), benefit from erlo-
tinib was seen in both groups. Similarly, there was no treatment-by-
histology interaction in the immediate versus delayed docetaxel study
or the IFCT-GFPC-0502 trial for either gemcitabine or erlotinib.
Biomarker analysis has suggested possible patient subgroups,
which might derive greater or lesser benefit from treatment with
EGFR-TKIs. It is clear that PFS, but not OS, is significantly better in
patients with EGFR mutations. In the context of EGFR-mutant lung
cancer,studiesoffirst-lineEGFR-TKIsversusstandardplatinumchem-
otherapy have demonstrated a large benefit in terms of response rate,
PFS, and QoL favoring the TKIs.39,40 Even in the absence of a
survival improvement, we feel that these patients are best served
with first-line treatment with an EGFR-TKI, which should not be
reserved for second-line or maintenance therapy. Patients with K-ras
mutation, however, seem to have less benefit. In the SATURN trial,
PFS was statistically significant only for patients with wild-type tumors
(HR, 0.70; P  .0009 v HR, 0.77; P  .2246 for mutant tumors),
although on further analysis there was no interaction with treatment
effect for this variable (P .95).41 Similarly,K-raswild-type status was
associated with a PFS HR of 0.67 (95% CI, 049 to 0.91) in the ATLAS
study, compared to a HR of 0.93 (95% CI, 0.55 to 1.56) for mutant
tumors. In addition, there is a long line of publications, which show
questionable benefit to therapy with EGFR-TKIs for patients with
K-ras mutant NSCLC,42-44 and in one study, treatment with erlo-
tinib was associated with significantly worse survival in such pa-
tients.45 Although these data cannot be considered conclusive, a
practice favoring treatment with EGFR-TKIs for K-ras wild-type
patients is currently the most advisable approach.
Although the IFCT-GFPC 0502 is the only study to include both
the switch and continuation-maintenance approaches within the
same trial, the two experimental arms were compared separately to the
control group, and not to each other. However, the HR for both PFS
and preliminary OS analysis appeared to be more robust with contin-
uation chemotherapy compared to switch erlotinib. The question is
whether this difference, if real, reflects benefit from the strategy versus
the agent used. At this point, all studies with proven OS benefit have
followed a switch-maintenance strategy. On the basis of the design of
the Pemetrexed and Best Supportive Care Versus Placebo and Best
Supportive Care in Non-Small Cell Lung Cancer (JMEN) trial, it is
unclear whether the beneficial effect of pemetrexed maintenance ex-
tends to patients treated initially with pemetrexed. Several phase
III trials are underway to examine this issue. In the Point-Break study,
patients are being randomly assigned to either the ECOG 4599
regimen (carboplatin, paclitaxel, and bevacizumab, followed by bev-
acizumab) or the Patel regimen (carboplatin, pemetrexed, and bevaci-
zumab followed by pemetrexed and bevacizumab). In another
important study, patients with SD or responsive disease after 4 cycles
Table 5. Summary of Outcomes From Switch-Maintenance Trials
Characteristic
Study
Fidias22 JMEN23 SATURN24 ATLAS25 IFCT-GFPC 050215
Agent Docetaxel Pemetrexed Erlotinib Erlotinib  bevacizumab Erlotinib
Control arm treatment Delayed docetaxel Placebo Placebo Placebo  bevacizumab Observation
No. of patients 309 663 889 768 310
PFS, months 5.7 v 2.7 4.0 v 2.0 12.3 v 11.1 weeks 4.76 v 3.75 2.9 v 1.9
PFS for nonsquamous cell histology 4.4 v 1.8
Hazard ratio 0.63 0.60 0.71 0.72 0.82
Hazard ratio for nonsquamous cell histology 0.47
P  .001  .001  .001 .0012 .002
Salvage treatment, % 63 67 72 55.5 81.9
OS, months 12.3 v 9.7 13.4 v 10.6 12.0 v 11.0 15.9 v 13.9 NA
OS for nonsquamous cell histology 15.5 v 10.3
Hazard ratio 0.80 0.79 0.81 0.9 0.91
Hazard ratio for nonsquamous cell histology 0.70
P .085 .012 .0088 .2686 NA
P for nonsquamous cell histology .002
Abbreviations: JMEN, Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer; SATURN, Sequential Tarceva
in Unresectable Lung Cancer; ATLAS, Assessment of Treatment With Lisinopril and Survival; IFCT-GFPC, Intergroupe Francophone de Cancerologie Thoracique-
Groupe Francais de Pneumo-Cancerologie; PFS, progression-free survival; OS, overall survival; NA, not available.
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of cisplatin and pemetrexed are randomly assigned to either pem-
etrexed or to observation. Lastly, in A Study of Avastin (Bevacizumab)
With or Without Pemetrexed as Maintenance Therapy After Avastin
in First Line in Patients With Non-Squamous Non-Small Cell Lung
Cancer (AVAPERL1), patients are randomly assigned to either bev-
acizumab alone or bevacizumab and pemetrexed after 4 cycles of
induction therapy with cisplatin, pemetrexed, and bevacizumab.
Apart from the ATLAS trial, results of recent maintenance studies
do not take into account the use of bevacizumab. Results from a phase
III trial (Gynecologic Oncology Group 218) in advanced ovarian can-
cer examining the use of maintenance bevacizumab were presented in
the 2010 ASCO meeting.46 Relative to patients treated with chemo-
therapy alone, the HR for progression or death was 0.908 (P .16) for
the group treated with first-line chemotherapy/bevacizumab, but
without maintenance. In contrast, the HR was 0.717 (P .0001) for
those patients treated with maintenance bevacizumab. These in-
triguing results suggest a beneficial antitumor effect of antiangio-
genic maintenance therapy, which may translate in other tumor
types as well. The Eastern Cooperative Oncology Group is plan-
ning a randomized trial of three different maintenance strategies in
patients with NSCLC after four cycles of carboplatin, paclitaxel,
and bevacizumab: pemetrexed alone, bevacizumab alone, or pem-
etrexed plus bevacizumab.
What is the most appropriate study end point? Debate on main-
tenance therapy is, in part, a debate about timing of therapy in
NSCLC. Therefore, OS, and not PFS, is the most appropriate end
point. Even if a survival benefit is demonstrated, patients often have
different priorities, placing greater importance on improvements in
QoL.47 Older studies occasionally showed worsening in QoL with
prolongation of chemotherapy, although such studies often included
cisplatin regimens. More recent studies have shown no detriment in
QoL when comparing different durations of chemotherapy11 or when
comparing delayed versus immediate second-line therapy.22,27 In the
docetaxel study, there was no significant difference between the im-
mediate docetaxel and delayed docetaxel arms with respect to global
QoL (improvement: 15.6% for both arms; worsening: immediate
11.0% and delayed 18.4%; overall P  .76). Symptom control data
from the SATURN study augment this point: although there was no
difference in time to deterioration in QoL by Functional Assessment
of Cancer Therapy-Lung in the two arms (HR, 0.96), there was an
improvement in time to pain and time to analgesic use in favor of the
erlotinib arm (HR, 0.61 and 0.66, respectively). In the pemetrexed
study, drug-related toxicity was greater for the pemetrexed arm, in-
cluding anemia, fatigue, anorexia, and nausea. However, time to
symptom worsening analysis favored pemetrexed maintenance for
control of pain (6.1 v 4.6 months; P .041) and hemoptysis.23
Ultimately, physicians and patients will have to decide on the
timing of additional chemotherapy, based on prior treatment toler-
ance, the expected acute toxicities of the proposed regimen, and po-
tential benefits in terms of survival and symptom control.
With regard to future developments in the treatment of patients
with advanced NSCLC, special attention will be paid to the identifica-
tion of patient subgroups more or less likely to benefit from mainte-
nance therapy, as this approach becomes a new therapeutic option.
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